 |
| |
| |
|
 |
Chief Executive Officer |
|
| |
| Dr. Rosenberg is responsible for providing vision, leadership and direction to IPM. Previously, Dr. Rosenberg was the scientific director for the HIV Prevention Trials Network at Family Health International from 1999 to 2002. In that role, she assured scientific and operational coordination for domestic and international clinical trials designed to prevent HIV transmission from mother to child and through sexual contact and through injection drug use. From 1987 to 1999, Dr. Rosenberg worked in several capacities at the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health. In her role as senior scientist at NIAID’s Division of AIDS, she was responsible for HIV-prevention clinical trials in adult populations. As assistant director for prevention research, she coordinated prevention activities for HIV and other sexually transmitted infections as well as tuberculosis, represented NIH on the Public Health Service Task Force to Combat Multi-Drug Resistant TB and co-chaired the TB Research Subcommittee. Dr. Rosenberg received her undergraduate degree in biology and mathematics from Douglass College, Rutgers University; a master’s degree (S.M.) in epidemiology and a doctoral degree (ScD) in microbiology from the Harvard School of Public Health. |
|
|
 |
Chief Operating Officer and Chief Financial Officer |
|
| |
Mr. Goldrich is responsible for providing strategic guidance to the IPM senior leadership team and works collaboratively to improve operations across the organization and within IPM’s global partner networks. Additionally, he oversees strategic fiscal planning, budgeting, compliance with accounting standards and internal controls. Mr. Goldrich joined IPM with a 40-year career of managing research institutions and scientific and clinical programs in the government, academia, corporate and nonprofit sectors. Before joining IPM Mr. Goldrich served as the executive vice president and chief operating officer (COO) for the International AIDS Vaccine Initiative (IAVI), where he successfully led efforts to strengthen the organization’s operational structure worldwide. Mr. Goldrich was the vice president for research operations at the Beth Israel Deaconess Medical Center at Harvard Medical School in Boston prior to his work at IAVI, and he also served as the founding COO for the Institute of Human Virology (IHV) at the University of Maryland. During his early 25-year career at the National Institutes of Health (NIH) he served as the COO at the Warren Magnuson Clinical Center, the National Institute of Allergy and Infectious Diseases (NIAID) and at the National Cancer Institute (NCI). Mr. Goldrich received his bachelor’s degree in accounting from the University of Maryland and also holds an M.B.A in finance from Loyola University. |
|
|
|
Chief Medical Officer |
|
| |
| Dr. Nel is responsible for IPM’s clinical trials and international clinical site development. Previously, Dr. Nel worked as an independent clinical research consultant in the drug development process. She has significant experience in all levels of clinical research and in a broad range of therapeutic areas, and she has worked as an investigator in clinical research for more than 20 years. Before serving as a consultant, Dr. Nel worked for Quintiles in South Africa, and was the founding staff member of its Cape Town office, responsible for the general management of the office and clinical operations. In 2004, Dr. Nel became head of business development for Quintiles, Africa. Prior to joining Quintiles, she worked as a medical officer in numerous therapeutic areas and lectured in pharmacology, pulmonology and toxicology at the Tygerberg campus of the University of Stellenbosch Medical School. Dr. Nel also has been involved with the South African Navy base at Simon’s Town as a part-time lecturer in marine and submarine medicine. Dr. Nel obtained a bachelor’s degree (B.Sc.) in clinical pharmacology from the University of Stellenbosch, South Africa, where she also earned a PhD and qualified as a medical doctor. |
|
|
|
Chief of External Relations |
|
| |
| Ms. Norick is responsible for IPM’s strategic engagement with key constituencies and stakeholders worldwide and coordination of IPM’s external outreach across all programs. Ms. Norick has worked on behalf of major U.S. non-governmental organizations involved in developing safe and effective microbicides for nearly a decade. Before entering the microbicide field, she served as senior legislative advisor for many years in the U.S. House of Representatives and Senate, specializing in national security and foreign policy. During her tenure, Ms. Norick routinely managed relevant negotiations on a broad range of issues with foreign government leaders and representatives, United Nations agencies, officials from the U.S. Departments of State and Defense, the U.S. Agency for International Development and others. In a variety of professional capacities, she has traveled extensively in Africa, the Middle East, Europe, Latin America and Asia. Throughout her career, Ms. Norick has been committed to improving the economic, social and health status of women and their families in the developing world. A former Peace Corps volunteer in central Africa, she holds a master’s degree from American University’s School of International Service. |
|
|
|
Chief of Product Development |
|
| |
| Dr. Romano is responsible for research and development (R&D) activities at IPM, which include internal drug development projects as well as externally funded microbicide R&D activities. Prior to joining the organization, Dr. Romano served as vice president of research at Biosyn, Inc., a private corporation that develops microbicides against HIV and other STI’s. Dr. Romano’s research at Biosyn focused on HIV-specific and broad spectrum anti-infectives and combination microbicides. Prior to focusing on microbicide research, he spent 10 years in the HIV field at ABL Inc., a subsidiary of AKZO-Nobel. There, he was involved in research related to Kaposi’s sarcoma, cytokine expression and vaccine development. He was also responsible for developing novel diagnostic technologies targeting HIV infection, viral load quantitation and immune response monitoring. He spent three years at the National Cancer Institute of the U.S. National Institutes of Health where his research involved molecular characterization of tumor suppressor genes. Dr. Romano is a molecular biologist and received a BS in biology from Lehigh University, and a MS and PhD in microbiology from Rutgers University. |
|
|
|
Chief of Regulatory Affairs & Quality Assurance |
|
| |
| Dr. Nardi is responsible for strategic planning and implementation of quality assurance measures in IPM’s product development, as well as for regulatory strategy and filings for IPM products. Dr. Nardi joined IPM in October of 2009 with more than 32 years of experience in drug development, including regulatory affairs. Dr. Nardi has extensive experience in drug discovery, regulatory affairs and manufacturing as well as in corporate management, including strategic direction assessments and integration of commercial research and development goals. Before joining IPM, he served as the chief scientific officer and executive vice president for BioValve Technologies, a company developing new drug device combination products to deliver novel therapeutics. Dr. Nardi also oversaw corporate Research and Development (R&D), worldwide regulatory affairs, R&D portfolio management and business development as the senior vice president and chief scientific officer at PDI, Inc. From 1996 to 2002, he worked at Ferring Pharmaceuticals, where he held various positions in R&D, including chief scientific officer and executive vice president of global R&D. Dr. Nardi holds a Ph.D. in pharmacology/toxicology from Rutgers University, and he earned his B.A. in biology at Temple University. |
|
|
|
Chief Human Resources Officer |
|
| |
Dr. Ross is responsible for IPM's talent and organizational strategies including staffing, retention and employee development; compensation, benefits and employee relations; and management, leadership and organization development. Dr. Ross has extensive experience leading the human resources function in both corporate and nonprofit organizations. Before joining IPM, Dr. Ross served as the executive vice president and CHRO at Arbitron, where she assisted the board of directors, CEO and executive staff in developing and executing the company's strategic plan. Dr. Ross also served as the vice president for Organization Development and Corporate Communication at Chevy Chase FSB, where she led the company’s efforts to design and implement organizational structures and talent strategies to support rapid expansion. Dr. Ross has served on numerous nonprofit boards and is currently chairwoman of the Board for the Human Resource Planning Society. She holds a PhD in organizational behavior and development from the School of Business and Public Management of The George Washington University, where she serves as adjunct faculty; and she earned a Masters in human resource management from the American University Kogod School of Business. |
|
|
|
Executive Director for Operations and Planning |
|
| |
| Ms. McCord oversees planning related to IPM’s drug development activities as well as manages the Contracts Group and the newly formed Manufacturing Department, including the CTM Facility in Bethlehem, PA. Prior to joining IPM, Ms. McCord served as vice president of product development at Biosyn, Inc., a corporation developing microbicides against HIV and other STI’s. Ms. McCord spent 14 years at Biosyn where she was responsible for the drug development efforts of compounds in its microbicide pipeline. She oversaw development of the lead candidate microbicide from post-discovery through the initiation of Phase III trials in Africa and the United States, and advanced a second compound from early preclinical into a series of international Phase I safety studies. Ms. McCord has extensive experience managing NIH grants and contracts, and NGO grant awards. She has served on the board of the California Microbicide Initiative and on a number of panels and working groups focusing on microbicides. Ms. McCord has a Bachelor of Applied Science from the School of Engineering and Applied Science at the University of Pennsylvania and a BS in Economics from the Wharton School at the University of Pennsylvania. |
|
|
|
Executive Director of External Relations, Europe |
|
| |
| Dr. Mertenskoetter leads IPM’s overall engagement in Europe and directs the work of IPM Belgium. Dr. Mertenskoetter is a former HIV/AIDS physician, and he most recently served as the medical director of Gilead Sciences GmbH, Germany from 2002 to 2007. There he was responsible for developing and implementing Gilead’s clinical research program in HIV and viral hepatitis among other areas. Before that, he was director of medical communications at GlaxoSmithKline. Over the years, Dr. Mertenskoetter has worked in various public-private research programs focusing on the epidemiology of HIV and AIDS, observational research in HIV care, international HIV pharmacovigilance and the introduction of ART for patients in developing countries. Dr. Mertenskoetter received his medical doctorate from the University of Hamburg and his training in tropical medicine and parasitology from the Bernhard Nocht Institute. |
|
|
|
|
| |
IPM Headquarters: 8401 Colesville Road • Suite 200 • Silver Spring, MD 20910
(p) +1 301-608-2221 • (f) +1 301-608-2241
© Copyright, International Partnership for Microbicides |
|
| |
